Fact sheets & publications
The following is a selection of recent fact sheets and policy guidance documents produced by IAVI in partnership with key stakeholders.
About IAVI
IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.
The world needs an HIV vaccine
The only way to end HIV/AIDS as a public health problem of global importance is with a vaccine. IAVI remains committed to developing a safe, effective, globally useful one.
The urgent need for a TB vaccine
A vaccine is necessary to end the TB epidemic. IAVI and partners continue to make strides to reach this goal.
Emerging infectious diseases vaccines
IAVI is applying its vaccine development expertise and working with a group of expert international partners to develop vaccines to prevent emerging infectious diseases.
Antibodies for HIV prevention
IAVI and partners are applying their expertise gained from HIV vaccine research to produce what could be a breakthrough in the fight against HIV/AIDS: an injection of bnAbs to prevent HIV infection.
MTBVAC: the only live-attenuated Mtb vaccine in development
IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.
Coronavirus vaccine program
IAVI and partners are leveraging our extensive vaccine development expertise to develop a vaccine to prevent COVID-19, with a focus on equitable global access.
IAVI Design and Development Lab
The IAVI Vaccine Design and Development Lab generates and develops innovative HIV and emerging infectious diseases vaccine candidates to address global public health needs.
ADVANCE
ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) is a 5-year cooperative agreement extended through June 2026 with the U.S. Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).